Allergan to pay $200M to settle New York State’s lawsuit over deceptive marketing of opioids

0
170

Allergan is also prohibited from providing financial incentives to its employees selling and marketing its opioids products. The company is also not allowed to directly or indirectly, provide financial support or in-kind support to any third party that primarily engages in promoting opioid products.

Furthermore, the company is prohibited from lobbying federal, state, or local legislative or regulatory authorities about opioids.

Finally, it is required to provide the public, patients, and healthcare providers with additional information about opioids.

In a statement, AG James said, “For more than two decades, opioids have wreaked havoc on New Yorkers and Americans across the nation — causing pain, addiction, and death. Our ongoing trial has been about the role companies like Allergan and its predecessors played in helping grow this epidemic, profiting while Americans suffered. But today’s agreement keeps Allergan out of the opioid business for the next decade and has the company paying as much as $200 million.”